Skip Navigation

Mycobacteria

Contacts

Christine Sizemore - Section Chief

  • Cooperative Agreements for Product Development
  • PK/PD
  • Clinical drug resistance
  • Molecular immunology

Robert Goldman

  • Drug discovery
  • Assay development for drug discovery
  • Target identification
  • Hit identification, lead development
  • Pre-clinical drug development strategies
  • Medicinal chemistry studies
  • Molecular mechanism of mycobacterial drug resistance

Gail Jacobs

  • All Fs and Ks
  • Diagnostics development
  • Diagnostics for implementation – all
  • Mycobacterial physiology
  • Bacterial Cell-to-cell signaling
  • Bacterial virulence
  • Bacterial secretion and role in host/pathogen interactions

Karen Lacourciere

  • Genetic determinations of mycobacterial disease
  • Mycobacterial gene regulation
  • Genome wide associations
  • Sequencing and Genomics
  • Proteomics technology and applications
  • Metabolomics
  • Systems Biology
  • Enzymology
  • Microarray technology development
  • Nanotechnology
  • Imaging technology
  • Target discovery technologies for drugs, vaccines and diagnostics
  • Development of molecular and genetic tools for Mycobacterial research

Robin Mason

  • Mycobacterial Epidemiology
  • Domestic and international clinical research/studies/trials under grants and cooperative agreements
  • Clinical trials under cooperative agreements for drugs
  • Clinical studies in leprosy under grants

Dikoe Makhene, Medical Officer

  • Medical oversight over all studies involving human subjects – grants and contracts
  • Contact for all clinical trials, R34 concepts, U01 clinical trial concepts
  • Representative of Section to OCRA and ORA on all medical and human subjects research
  • Representative for all aspects of pediatric clinical research 
  • NIAID representative for clinical trials for TB

Tina Parker

  • Immunology of Host/Pathogen interactions
  • Animal models of infection and disease
  • Animal models for testing of vaccines, diagnostics and drugs
  • Vaccine and adjuvant development
  • Clinical trial cooperative agreements for vaccines

RDB - Tuberculosis, Leprosy, and Other Mycobacterial Diseases Section 301-496-5305

back to top

Last Updated February 25, 2009

Last Reviewed February 25, 2009